Invitae

Ciitizen Corporation operates a digital healthcare platform that empowers patients to collect, organize, and share their personal health information, including genomic data, lab results, and advanced directives. Founded in 2017 and based in Palo Alto, California, Ciitizen aims to provide individuals with comprehensive control over their health data, facilitating seamless sharing with caregivers, researchers, and other relevant parties. The platform addresses the limitations of existing health information systems, which often provide only minimal data and require extensive manual efforts to extract insights. By normalizing unstructured health information into actionable visualizations, Ciitizen enhances the ability of patients, caregivers, and clinicians to access and utilize vital health insights efficiently. The company is led by CEO Anil Sethi and is supported by notable investors, including Andreessen Horowitz and Verily, positioning it as a key player in the evolving landscape of patient-centered healthcare data management.

Genosity is a life science biotechnology company focused on providing tools and services for clinical research applications of genomics. They provide novel software solutions and laboratory services for both somatic and germline applications to enable their strategic partners to fully realize the value of precision medicine for both the research and clinical markets.

One Codex is a data platform focused on applied microbial genomics, offering bioinformatics solutions that facilitate applications in clinical diagnostics, food safety, and biosecurity. The company specializes in developing scalable and secure platforms for metagenomics and microbial genomics, emphasizing usability to cater to applied microbiologists. By providing access to a comprehensive microbial reference database, One Codex enables rapid and straightforward microbiome analysis, enhancing the capabilities of professionals in the field.

ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.

Diploid is a biotechnology services provider that specializes in clinical genome interpretation. The company has developed software that utilizes artificial intelligence to analyze human genome data, transforming raw genetic information into comprehensive reports. These reports identify novel variants responsible for genetic disorders and rare diseases. By outsourcing clinical genome interpretation to Diploid, hospitals and clinical laboratories can alleviate their workload and enhance diagnostic accuracy, ultimately improving patient care.

Genelex Corporation, based in Seattle, Washington, operates as a DNA testing laboratory specializing in pharmacogenetic testing aimed at personalized medication management. Founded in 1987, the company offers a range of services, including DNA sensitivity tests, parentage and forensic DNA testing, and ancestry DNA testing. Its GeneMedRx software helps healthcare professionals predict potential drug interactions and assess the risks associated with medications based on a patient’s genetic profile. Genelex also provides various at-home and legally admissible DNA tests for paternity, maternity, and genetic ancestry. Through its innovative analytics and advanced laboratory facilities, Genelex is committed to reducing the risk of adverse drug events and enhancing patient safety in medication prescribing. As of April 2020, Genelex operates as a subsidiary of Invitae Corporation.

YouScript Incorporated, founded in 2016 and headquartered in Seattle, Washington, specializes in precision prescribing software solutions aimed at enhancing medication management for healthcare providers. The company focuses on delivering innovative tools that assist clinicians in making informed prescribing decisions, ultimately improving patient outcomes through personalized medication strategies.

Clear Genetics, Inc. is a digital health company that specializes in providing genetic counseling services to women, healthcare providers, and health systems. Founded in 2016 and based in San Francisco, California, the company offers a web application called Clearancy, which delivers personalized genetic information for patients undergoing genetic testing and their medical practitioners. Clear Genetics focuses on various medical specialties, including prenatal care, cardiology, carrier screening, hereditary cancer, and pediatrics. By partnering with health systems, laboratories, and academic institutions, Clear Genetics aims to enhance patient access to genetic counseling and testing, facilitating the thoughtful integration of genetics into routine patient care. As of November 2019, Clear Genetics operates as a subsidiary of Invitae Corporation.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.

CombiMatrix Corporation, now a subsidiary of Invitae Corporation since 2017, specializes in clinical molecular diagnostic laboratory services in the United States. The company primarily focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. CombiMatrix employs advanced technologies such as single nucleotide polymorphism analysis, chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization, and high-resolution karyotyping to detect genetic abnormalities that traditional methods may miss. Its services are utilized by physicians, hospitals, and clinics, catering to commercial insurance companies, government payors, and individual patients. Founded in 1995 and originally based in Mukilteo, Washington, CombiMatrix has developed proprietary technologies and products for genetic analysis and diagnostics, enhancing patient care through innovative molecular diagnostics.

Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CancerGene Connect represents the power of evolving technology in healthcare science. With each generation of improvement, our platform makes significant strides in pedigree generation and risk modeling–bringing increasingly powerful connections to thousands of patients and practices.

AltaVoice is a patient-centered data company in Silicon Valley with an innovative story and business model that optimizes the search for better treatments for diseases. We build and host Patient Insights Networks (PINs). PINs are ideal for collecting, curating and sharing patient and clinician reported health data. We work with drug developers, advocacy organizations and academic researchers, uniting them with patients to help improve lives. Via our PINs, we deliver patient insights faster, and for far less, than traditional registries and CRO organizations. Our approach fosters ongoing patient engagement and enables advocacy organizations worldwide to unite their data collection efforts while maintaining their brand presence. As you’ll see from our Mission, we are committed to breaking down the data silos that impede medical advances. Since 2007, we have developed programs for more than 400 diseases through our work with over 100 advocacy groups, NIH, PCORI, biotech and pharmaceutical companies. In 2016, we were honored by Vice President Joe Biden’s invitation to participate in the Cancer Moonshot events at the Whitehouse in recognition of our pioneering work.